Related Experiment Videos
Kasabach-merritt syndrome
Sheilagh Maguiness1, Lyn Guenther
1University of Western Ontario, London, Ontario, Canada.
Background:
Kasabach-Merritt syndrome (KMS) is a consumptive coagulopathy associated with the presence of a large vascular lesion. It is often a frustrating condition to treat and it carries a high mortality rate. There are currently no known treatment guidelines. Kasabach-Merritt syndrome is associated with kaposiform hemangioendothelioma (KHE) and tufted angioma (TA); these lesions, when associated with KMS, are locally invasive, aggressive vascular tumors. Treatment options include supportive care, local therapies, and drug and surgical management. In most recent case reports, a multimodal approach to therapy is taken.
Objective And Conclusion:
The objective of this article is to provide a comprehensive review of KMS and give an up-to-date summary of treatment options. The clinical presentation, laboratory findings, vascular pathology, and pathophysiology will also be discussed.
Insights
Kasabach-Merritt syndrome (KMS) is a rare coagulopathy linked to vascular tumors. This review summarizes current treatment strategies for this challenging condition.
Area of Science:
- Vascular Medicine
- Pediatric Hematology
- Oncology
Background:
- Kasabach-Merritt syndrome (KMS) is a consumptive coagulopathy associated with large vascular lesions like kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
- KMS presents a high mortality rate and lacks established treatment guidelines, often requiring a multimodal therapeutic approach.
- These aggressive vascular tumors are locally invasive, posing significant treatment challenges.
Purpose of the Study:
- To provide a comprehensive review of Kasabach-Merritt syndrome (KMS).
- To summarize current and emerging treatment options for KMS.
- To discuss the clinical presentation, laboratory findings, vascular pathology, and pathophysiology of KMS.
Main Methods:
- Literature review of case reports and existing studies on Kasabach-Merritt syndrome.
- Analysis of treatment modalities including supportive care, local therapies, pharmacotherapy, and surgical interventions.
- Synthesis of information on clinical, laboratory, and pathological aspects of KMS.
Main Results:
- Kasabach-Merritt syndrome (KMS) is characterized by a consumptive coagulopathy and aggressive vascular tumors (KHE, TA).
- Treatment is often multimodal, involving supportive care, local therapies, and systemic drug or surgical management.
- A comprehensive understanding of KMS pathophysiology is crucial for effective management.
Conclusions:
- Kasabach-Merritt syndrome (KMS) requires a multidisciplinary approach due to its complexity and high mortality.
- Further research is needed to establish evidence-based treatment guidelines for KMS.
- Early diagnosis and tailored therapeutic strategies are essential for improving patient outcomes.